Wockhardt Ltd
Wockhardt Ltd Q3 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Wockhardt Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY25 Revenue: Rs. Q3 FY25 EBITDA: Rs.
From Wockhardt Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Revenue: Rs. 725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. 709 crore).
- 9MFY25 Revenue: Rs. 2,290 crore versus Rs. 2,129 crore in 9MFY24, an 8% year-on-year growth.
- EBITDA in Q3 FY25 improved 50% year-on-year to Rs. 100 crore from Rs. 67 crore in Q3 FY24.
- EBITDA for 9MFY25 stood at Rs. 339 crore, up 89% compared to Rs. 180 crore for 9MFY24.
- India Branded Business Q3 FY25 revenue: Rs. 114 crore; 9MFY25 revenue: Rs. 361 crore.
- Irish Business Q3 FY25 revenue: Rs. 46 crore; 9MFY25 revenue: Rs. 134 crore.
- US Business Q3 FY25 revenue: Rs. 25 crore; 9MFY25 revenue: Rs. 85 crore.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key investor presentation takeaways from NGL Fine Chem Ltd's Q
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation — and how it ra
- Themis Medicare Ltd (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY25 investor presentation — and how i
- Lincoln Pharmaceuticals Ltd (Q3 FY25)
EBITDA:** ₹32.2 crore, up 16% year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY25 investor presentation — and how it ra
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY25 results?
Q3 FY25 Revenue: Rs. Q3 FY25 EBITDA: Rs.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
The presentation does not explicitly mention any capex, capacity expansion, or new plant/project details, including amounts, status, or timelines.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.